A blood‐based biomarker that not only reliably reflects cerebral Aβ and tau pathologies like CSF biomarkers but also independently represents AD pathology in the diverse study population has huge potential as a frequent disease monitoring in clinical and therapeutic settings. Here, MAPT is linked to Alzheimer disease.